Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Confidential contracting

- PMLiVE

Repositive appoints scientific lead

Manuel Corpas joins the genome software company

- PMLiVE

Nestlé Health Science buys medical device firm

Acquisition of UK's Phagenesis expected to be completed by 2019

- PMLiVE

Clinton takes aim at pharma pricing once again

Pledges to establish new enforcement powers to address “unjustified price hikes”

- PMLiVE

Merck decision to drop odanacatib lifts UCB/Amgen

Pulls plug on osteoporosis candidate after studies show high risk of stroke

Kirsten Drejer steps down as Symphogen CEO

The biotech’s CFO Martin Olin succeeds her in the role

EFPIA director general Richard Bergström resigns

Will remain in the role until a successor has been selected

- PMLiVE

SO What Global launches patient engagement venture

New agency will focus on aiding pharma companies’ pursuit of patient-centricity

- PMLiVE

Medicines Discovery Catapult appoints CEO

Chris Molloy will take up the lead role in November this year

- PMLiVE

Amgen agrees to take Cytokinetics’ heart failure drug into phase III

Phase II results showed significant cardiac function benefit and no adverse safety signals

Roche Basel Switzerland

Roche’s checkpoint inhibitor Tecentriq aces lung cancer trial

Second-line therapy showed overall survival benefit irrespective of PD-L1 status

Roche - Basel

Roche re-joins UK pharma’s trade body the ABPI

Firm left in 2009 following its suspension for a major Code of Practice breach 

- PMLiVE

Alzheimer’s disease: reviewing the immediate treatment horizon

Account Manager Stuart Goodman takes a look at some of the promising categories of Phase 3 treatments that could soon be available to patients with Alzheimer's disease.

Blue Latitude Health

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links